AR and neoplasm: ARSTAs (e.g., abiraterone acetate and enzalutamide) could induce AR-V7 expression in circulating tumor cells, whereas chemotherapy (e.g., docetaxel and cabazitaxel) diminished the AR-V7 expression [33,34].